Search Results
160 items found for "Targeted therapy"
- Ep 84 with Rosie Dawaliby
Rosie Dawaliby "I’m an expert in early-stage drug discovery, targeting membrane proteins, especially In 2016, I joined a company that specialized in therapeutic candidate discovery targeting GPCR ( Confo
- Ep 144 with Dr Aurélien Rizk
Yamina asked if there was ever a consideration to work on targets other than GPCRs, to which Aurelien discussion concluded with the idea that ligand residence time could be an important factor in effective therapy They also shared their preference for small molecule therapies over protein therapeutics. Aurelien Rizk confirmed his attendance at the upcoming GPCR-Targeted Drug Discovery Summit in Boston.
- Chemoattractant receptor signaling in humoral immunity
However, the molecular mechanisms by which individual GRKs are selectively targeted to GPCRs have been the context of humoral immunity and discuss the potential of the COMMD3/8 complex as a therapeutic target
- The binding mechanism of an anti-multiple myeloma antibody to the human GPRC5D homodimer
Its high expression on the surface of multiple myeloma cells has rendered it an attractive target for organization of this unconventional Class C GPCR but also hold the potential to advance drug development targeting
- Exploration of prognostic and treatment markers in hepatocellular carcinoma via GPCR-related genes analysis
protein-coupled receptors (GPCRs), the biggest family of signaling receptors, account for 34 % of all the drug targets protein-protein interaction (PPI) mechanisms were explored; hub genes and micro ribonucleic acid (miRNA)-target HCC prognostic prediction model was constructed by only GPCR-related genes, which are all potential targets
- Receptor autoantibodies: Associations with cardiac markers, histology, and function in human non-ischaemic heart failure
Here, we use validated and certified immune assays presenting native receptors as binding targets. cardio-pathogenic role of GPCR autoantibodies and suggest that further investigations are required before specific therapies
- From odor to oncology: non-canonical odorant receptors in cancer
These findings shed light on the potential of non-canonical odorant receptors as therapeutic targets Ultimately, this review discusses the potential development of novel therapeutic strategies targeting
- Pan-cancer functional analysis of somatic mutations in G protein-coupled receptors
December 1, 2022 Abstract G Protein-coupled receptors (GPCRs) are the most frequently exploited drug target Our approach was confirmed by re-discovery of established cancer targets such as the LPA and mGlu receptor
- Principles of Pharmacology in Drug Discovery I
Candidate Molecules GPCRs have been and arguably still are the most prolific and fertile therapeutic drug targets this course describes the essential pharmacologic techniques and knowledge required to create a GPCR Target
- Principles of Pharmacology in Drug Discovery I
Candidate Molecules GPCRs have been and arguably still are the most prolific and fertile therapeutic drug targets this course describes the essential pharmacologic techniques and knowledge required to create a GPCR Target
- Ep 54 with Dr. JoAnn Trejo
important for increasing the fundamental knowledge of GPCR biology and for the identification of drug targets has important functions in hemostasis, thrombosis, inflammation, and cancer and is an important drug target
- Regulator of G protein signaling 16 restrains apoptosis in colorectal cancer through disrupting TRAF6-TAB2-TAK1-JNK/p38 MAPK signaling
remains a major global cause of cancer-related mortality, lacking effective biomarkers and therapeutic targets identifying Regulator of G protein signaling 16 (RGS16) as a prospective diagnostic and therapeutic target
- S1P Signaling Genes as Prominent Drivers of BCR-ABL1-Independent Imatinib Resistance and Six Herbal Compounds as Potential Drugs for Chronic Myeloid Leukemia
acid, colchicine, epigallocatechin-3-gallate, cucurbitacin B, and evodin-as potential drug candidates targeting Moreover, the S1P signaling genes are promising therapeutic targets and plausible new innovation avenues
- Purinergic GPCR-integrin interactions drive pancreatic cancer cell invasion
PDAC is elevated ATP levels, pointing to the purinergic axis as a potential attractive therapeutic target elucidates a novel GPCR-integrin interaction in cancer invasion, highlighting its potential for therapeutic targeting
- Advanced data analysis for GPCR pharmacology
pharmacology data analysis to a high level, as well as expertise that can be applied in drug discovery and target organizations in understanding and applying in vitro pharmacology data to advance drug discovery and target
- Exploiting frequent and specific expression of PRL3 in pediatric solid tumors for first-in-child use of PRL3-zumab humanized antibody
angiogenesis markers, and G-protein-coupled receptor (GPCR)-mitogen-activated protein kinase (MAPK) signaling targets A 28.6% reduction in maximum target lesion diameter was achieved when PRL3-zumab was administered concurrently
- Proteogenomic landscape and clinical characterization of GH-producing pituitary adenomas/somatotroph pituitary neuroendocrine tumors
Targeted capture sequencing and copy number analysis of 36 genes and nontargeted proteomics analysis Targeted capture sequencing revealed GNAS as the only driver gene, as previously reported.
- Ep 119 with Tanishka S. Saraf
Saraf " My research focuses on evaluating and targeting serotonin 1A receptors for therapeutic outcomes
- Ep 150 with Dr GPCR Team
in using G-Protein Coupled Receptors (GPCRs) that control virtually everything in the body as drug targets Her research centers on developing nanobody-ligand conjugates to target GPCRs, with a focus on receptors of South Florida, utilizing large-scale virtual drug screening to identify agonists and antagonists targeting
- Session III | Adhesion GPCR Workshop 2024 | Dr. GPCR Ecosystem
Human Adhesion GPCRs Stephanie Häfner Abstract "G Protein-coupled receptors (GPCRs) are common drug targets The NRS system has recently been validated in vivo by targeting the latrophilin-type aGPCR Cirl/ADGRL This tailored system aims to expedite the identification of drugs targeting the unique aGPCR receptor Our research aims to leverage this knowledge to identify novel pharmacological targets and contribute
- Ep 152 with Dr Arthur Christopoulos
Additionally, they covered the importance of target product profiles, reproducibility in experiments, Arthur's strategy of consulting drug companies and targeting their posters at conferences was also shared They both agreed on the necessity of understanding the target product for an allosteric modulator and TPP, Allosteric Modulators, and Reproducibility Yamina and Arthur discussed the concept of a target product
- Ep 81 with Dr. Christel Menet
today we are more than 60 :) I have fun every day, and I love working with GPCRs. they are such great targets
- GPCR Retreat 2023 - Part II
as a Postdoctoral Fellow to explore novel G protein-coupled receptor (GPCR) candidates that can be targeted signaling and degradation of GPCRs in disease states to help test the feasibility of using protein-targeted
- Ep 117 with Dr. Pierre Eftekhari
The latter mainly in target deconvolution and patient stratification." Dr.
- Ep 01 with Dr. Paul Insel
Paul and his team focus on previously unrecognized receptors with the hopes to use these as novel drug targets
- Ep 99 with Yamina Berchihce
in using G-Protein Coupled Receptors (GPCRs) that control virtually everything in the body as drug targets
- Ep 116 with Dr. Shivani Sachdev
Her research centers on developing nanobody-ligand conjugates to target GPCRs, with a focus on receptors
- Ep 58 with Dr. Juan José Fung
José Fung is a Principal Scientist at GPCR Therapeutics, Inc , a drug discovery company focused on targeting